Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
API
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-thiophenepropanoic Acid, Alpha-((2-butyl-1-((4- Carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
2. Eprosartan
3. Sk And F 108566
4. Skf-108566
5. Teveten
1. 144143-96-4
2. Teveten
3. Eprosartan Mesilate
4. Eprosartan Methanesulfonate
5. Eprosartan Monomethanesulfonate
6. Eprosartan (mesylate)
7. Sk&f 108566-j
8. Sk&f-108566-j
9. 8n2l1nx8s3
10. Chebi:48409
11. (e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic Acid, Monomethanesulfonate
12. 4-[[2-butyl-5-[(e)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic Acid;methanesulfonic Acid
13. Eprosartan Mesylate (usan)
14. Dsstox_cid_24217
15. Dsstox_rid_80124
16. Dsstox_gsid_44217
17. Eprosartan Mesylate [usan]
18. 4-({2-butyl-5-[(1e)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic Acid; Methanesulfonic Acid
19. Cas-144143-96-4
20. Eprosartan Mesylate [usan:ban]
21. Ncgc00164557-01
22. Unii-8n2l1nx8s3
23. Futuran
24. Navixen
25. Regulaten
26. Tevetenz
27. Epro-sartan Mesylate Dihydrate
28. Sr-05000001450
29. Eprosartanmesylate
30. Teveten Sb
31. Skf-108566j
32. Teveten (tn)
33. Schembl41396
34. Chembl1200987
35. Dtxsid7044217
36. Hms3262b17
37. Hms3885b05
38. Eprosartan Mesylate [vandf]
39. Eprosartan Mesilate [mart.]
40. Tox21_112186
41. Tox21_500808
42. Eprosartan Mesilate [who-dd]
43. Eprosartan Mesylate [usp-rs]
44. Hy-15834a
45. Mfcd08141807
46. S4102
47. Akos015994738
48. Eprosartan Mesylate, >=98% (hplc)
49. Tox21_112186_1
50. Am84399
51. Ccg-222112
52. Ks-1233
53. Eprosartan Mesylate [orange Book]
54. Ncgc00167505-02
55. Ncgc00261493-01
56. (e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1h-imidazol-1-yl)methyl)benzoic Acid Compound With Methanesulfonic Acid (1:1)
57. 2-thiophenepropanoic Acid, Alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1h-imidazol-5-yl)methylene)-, (e)-, Monomethanesulfonate
58. Eprosartan Mesylate [usp Monograph]
59. Eprosartan Monomethanesulfonate [mi]
60. E-145
61. E1161
62. Sw219286-1
63. A13747
64. D02082
65. Teveten Hct Component Eprosartan Mesylate
66. 143e964
67. A808180
68. Eprosartan Mesylate Component Of Teveten Hct
69. J-007923
70. Sr-05000001450-2
71. Q27121190
72. Eprosartan Mesylate, United States Pharmacopeia (usp) Reference Standard
73. (e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic Acid, Monomethanesulfonate
74. (e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic Acid, Monomethanesulphonate
75. (e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1h-imidazol-1-yl)methyl)benzoic Acid Methanesulfonic Acid Salt
76. (e)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1h-imidazol-5-yl)methylene)-2-thiophenepropanoic Acid Monomethanesulfonate
77. 2-thiophenepropanoic Acid, .alpha.-((2-butyl-1-((4-carboxyphenyl)methyl)-1h-imidazol-5-yl)methylene)-, (e)-, Monomethanesulfonate
78. 2-thiophenepropanoic Acid, .alpha.-((2-butyl-1-((4-carboxyphenyl)methyl)-1h-imidazol-5-yl)methylene)-, (e)-, Monomethanesulphonate
79. 2-thiophenepropanoic Acid, Alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-, (alphae)-, Methanesulfonate (1:1)
80. 4-({2-butyl-5-[(1e)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic Acid Methanesulfonate
81. 4-[[2-butyl-5-[(e)-2-carboxy-3-(2-thienyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic Acid; Methanesulfonic Acid
82. 4-[[2-butyl-5-[(e)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic Acid;methanesulfonic Acid.
83. Eprosartan Mesylate
84. Sk&f 108566
85. (?e)-?-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Methanesulfonate
Molecular Weight | 520.6 g/mol |
---|---|
Molecular Formula | C24H28N2O7S2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 10 |
Exact Mass | 520.13379358 g/mol |
Monoisotopic Mass | 520.13379358 g/mol |
Topological Polar Surface Area | 183 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 711 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Eprosartan mesylate |
PubMed Health | Eprosartan (By mouth) |
Drug Classes | Cardiovascular Agent, Renal Protective Agent |
Drug Label | TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. A selective non-peptide molecule, TEVETEN is chemically described as the monomethanesulfonate of (E )-2-butyl-1-(p-carboxybenzyl)--2-thienyl... |
Active Ingredient | Eprosartan mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Mylan Pharms |
2 of 4 | |
---|---|
Drug Name | Teveten |
Drug Label | TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. A selective non-peptide molecule, TEVETEN is chemically described as the monomethanesulfonate of (E )-2-butyl-1-(p-carboxybenzyl)--2-thienyl... |
Active Ingredient | Eprosartan mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Abbvie |
3 of 4 | |
---|---|
Drug Name | Eprosartan mesylate |
PubMed Health | Eprosartan (By mouth) |
Drug Classes | Cardiovascular Agent, Renal Protective Agent |
Drug Label | TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. A selective non-peptide molecule, TEVETEN is chemically described as the monomethanesulfonate of (E )-2-butyl-1-(p-carboxybenzyl)--2-thienyl... |
Active Ingredient | Eprosartan mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Mylan Pharms |
4 of 4 | |
---|---|
Drug Name | Teveten |
Drug Label | TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. A selective non-peptide molecule, TEVETEN is chemically described as the monomethanesulfonate of (E )-2-butyl-1-(p-carboxybenzyl)--2-thienyl... |
Active Ingredient | Eprosartan mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 600mg base; eq 400mg base |
Market Status | Prescription |
Company | Abbvie |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Angiotensin II Type 2 Receptor Blockers
Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR. (See all compounds classified as Angiotensin II Type 2 Receptor Blockers.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Eprosartan Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eprosartan Mesylate, including repackagers and relabelers. The FDA regulates Eprosartan Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eprosartan Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eprosartan Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eprosartan Mesylate supplier is an individual or a company that provides Eprosartan Mesylate active pharmaceutical ingredient (API) or Eprosartan Mesylate finished formulations upon request. The Eprosartan Mesylate suppliers may include Eprosartan Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Eprosartan Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Eprosartan Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Eprosartan Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Eprosartan Mesylate DMFs exist exist since differing nations have different regulations, such as Eprosartan Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Eprosartan Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Eprosartan Mesylate USDMF includes data on Eprosartan Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eprosartan Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Eprosartan Mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Eprosartan Mesylate Drug Master File in Korea (Eprosartan Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eprosartan Mesylate. The MFDS reviews the Eprosartan Mesylate KDMF as part of the drug registration process and uses the information provided in the Eprosartan Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Eprosartan Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eprosartan Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Eprosartan Mesylate suppliers with KDMF on PharmaCompass.
A Eprosartan Mesylate written confirmation (Eprosartan Mesylate WC) is an official document issued by a regulatory agency to a Eprosartan Mesylate manufacturer, verifying that the manufacturing facility of a Eprosartan Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eprosartan Mesylate APIs or Eprosartan Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Eprosartan Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Eprosartan Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eprosartan Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eprosartan Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eprosartan Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eprosartan Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eprosartan Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eprosartan Mesylate suppliers with NDC on PharmaCompass.
Eprosartan Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eprosartan Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eprosartan Mesylate GMP manufacturer or Eprosartan Mesylate GMP API supplier for your needs.
A Eprosartan Mesylate CoA (Certificate of Analysis) is a formal document that attests to Eprosartan Mesylate's compliance with Eprosartan Mesylate specifications and serves as a tool for batch-level quality control.
Eprosartan Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Eprosartan Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eprosartan Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Eprosartan Mesylate EP), Eprosartan Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eprosartan Mesylate USP).
LOOKING FOR A SUPPLIER?